Excess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti-TNF agents

Ian A. Clark1* and Bryce Vissel2

Abstract

The basic mechanism of the major neurodegenerative diseases, including neurogenic pain, needs to be agreed upon before rational treatments can be determined, but this knowledge is still in a state of flux. Most have agreed for decades that these disease states, both infectious and non-infectious, share arguments incriminating excitotoxicity induced by excessive extracellular cerebral glutamate. Excess cerebral levels of tumor necrosis factor (TNF) are also documented in the same group of disease states. However, no agreement exists on overarching mechanism for the harmful effects of excess TNF, nor, indeed how extracellular cerebral glutamate reaches toxic levels in these conditions. Here, we link the two, collecting and arguing the evidence that, across the range of neurodegenerative diseases, excessive TNF harms the central nervous system largely through causing extracellular glutamate to accumulate to levels high enough to inhibit synaptic activity or kill neurons and therefore their associated synapses as well. TNF can be predicted from the broader literature to cause this glutamate accumulation not only by increasing glutamate production by enhancing glutaminase, but in addition simultaneously reducing glutamate clearance by inhibiting re-uptake proteins. We also discuss the effects of a TNF receptor biological fusion protein (etanercept) and the indirect anti-TNF agents dithio-thalidomides, nilotinab, and cannabinoids on these neurological conditions. The therapeutic effects of 6-diazo-5-oxo-norleucine, ceptriaxone, and riluzole, agents unrelated to TNF but which either inhibit glutaminase or enhance re-uptake proteins, but do not do both, as would anti-TNF agents, are also discussed in this context. By pointing to excess extracellular glutamate as the target, these arguments greatly strengthen the case, put now for many years, to test appropriately delivered anti-TNF agents to treat neurodegenerative diseases in randomly controlled trials.

Keywords: TNF, Glutamate, Astrocyte, Synapse, Glutaminase, Re-entry proteins, Neurodegenerative disease, Neurogenic pain

Abbreviations: Aβ, Amyloid-β; ALS, Amyotrophic lateral sclerosis; AD, Alzheimer’s disease; BBB, Blood-brain barrier; CBD, Cannabidiol; CSF, Cerebrospinal fluid; DAMPs, Damage-associated molecular patterns; DON, 6-Diazo-5-oxo-norleucine; EAAT-2, Excitatory amino acid transporter 2; i.c.v., Intracerebroventricular; i.p., Intraperitoneally; HIV, Human immunodeficiency virus; IL-1β, Interleukin-1β; PAMPs, Pathogen-associated molecular patterns; PD, Parkinson’s disease; PP-2, Pyrazolopyrimidine-2; RA, Rheumatoid arthritis; T2DM, Type 2 diabetes mellitus; TBI, Traumatic brain injury; THC, Tetrahydrocannabinol; TLR, Toll-like receptor; TNF, Tumor necrosis factor
Background
The amyloid theory of Alzheimer's disease, and by extension other chronic neurodegenerative states, has dominated the field for decades. It has, however, in the face of the reality of numerous large clinical trials yielding no clinical improvement, lost momentum. A recent item on the Editor's Blog of the webpage of the Journal of Alzheimer's Disease entitled “Time to Dismount” (see http://www.j-alz.com/editors-blog/posts/time-dismount) eloquently again brings to the fore the long-held, widespread, and increasing unease among researchers [1–5]. Likewise, outcomes comparing in vivo human cerebral amyloid β (Aβ) deposition on Pittsburgh Compound B PET imaging have not generated optimism for the amyloid theory [6, 7]. Recent key epidemiological evidence from a large population in which administering regular subcutaneous etanercept over an extended period in treatment of rheumatoid arthritis (RA) patients was reported to reduce incidence of Alzheimer's disease (AD) [8], further reduces the likelihood of Aβ being the key to AD pathogenesis.

We have recently [9] reviewed the literature demonstrating that increased soluble Aβ does not cause direct damage but is one of the proinflammatory cytokine-induced damage-associated molecular patterns (DAMPs) recognized by toll-like receptors (TLRs). These receptors also recognize pathogen-associated molecular patterns (PAMPs) present on the surface of, for example, the microbes now widely agreed to be sometimes associated with AD [10]. Agonists of TLRs, which are on and in various types of cells, including those throughout the brain, release more of these same cytokines, including tumor necrosis factor (TNF). This is consistent with Aβ not inhibiting long-term potentiation in hippocampal slices from mice treated with anti-TNF agents, such as infliximab [11]. Clearly, from the literature we have recently quoted [9], Aβ is best regarded, along with S100 proteins and high-mobility group box 1 (HMGB1), as belonging to a class of DAMPs (secondary DAMPs) that exacerbates production of the proinflammatory cytokines responsible for their own increase, and induces them further, causing a forward feed chain reaction. Moreover, variation in levels of these other DAMPs of this same class, possessing the same TLR-mediated, TNF-generating activity in AD, may explain why normal aged patients can exhibit high Aβ plaque levels. It may also explain why removing soluble Aβ or its plaque, still the goal of the many clinical trials [12], does not retard human disease progression, since the other secondary DAMPs, S100 proteins and HMGB1, are still actively inducing TNF. In contrast, removing Aβ is successful in mouse transgenic models that have been designed to generate pathologically but artificially high Aβ [13].

Waning enthusiasm for the amyloid theory now allows many other approaches, including the last 10 years of animal studies, case reports, open trials, and off-label treatments of neurodegenerative diseases, based on neutralizing excessive levels of TNF within the brain, to receive more attention. Unaccountably, this neglected approach to neurodegenerative disease is sometimes still referred to as highly controversial [14]. This review provides the logic for increased extracellular cerebral glutatione being the central mechanism by which excessive TNF harms cerebral function and structure. TNF is the first endogenous mediator to be documented as simultaneously influencing extracellular cerebral levels of extracellular glutamate by both enhancing its release and reducing its re-uptake. Given the broad ramifications of glutamate-induced excitotoxicity in infectious and non-infectious disease, these additional layers of information about TNF provide insights with widespread therapeutic implications. In particular, it increasingly rationalizes accounts of the usefulness of neutralizing excess cerebral levels of TNF in neurodegenerative disease.

As well as providing sufficient background to enable the bigger picture of TNF in brain disease pathogenesis to be understood, we focus here on the implications of newer data, largely neglected in the world of neurodegenerative disease, on how this cytokine evidently controls levels of extracellular glutamate in the synaptic cleft. In brief, glutamate is the chief physiological excitatory neurotransmitter, essential of course in memory and learning, and indeed is functionally involved in virtually all activities of the nervous system. Glutamate's combination of functional importance and toxicity demands tight control over its release and re-uptake. Thus, as will be discussed, control by TNF of both of these functions gives treatments based on reducing excess cerebral levels of this cytokine a solid therapeutic foundation in neurodegenerative disease, in part because of its essential effects in driving excitotoxicity. In practice, we may usefully view TNF toxicity and glutamate toxicity as two perspectives on the one pathophysiological entity.

TNF, an extremely pleiotropic cytokine
TNF was recognized, and named, as an endogenous tumor killing agent [15], and 6 years later, its wider biological importance began to be appreciated through its roles in innate immunity and the pathogenesis of infectious disease ([16], reviewed in 2004 [17]). In due course, fundamental roles for this cytokine in physiological homeostasis [18] and non-infectious disease [19] began to be explored. After being recognized as an early step in the inflammatory cytokine cascade [20], TNF began to achieve its present wide acceptance as a master cytokine in disease pathogenesis through infliximab, the first of the specific neutralizing biological anti-TNF agents, becoming a striking clinical success in treating RA [21].
Others from this research group showed that TNF is a master cytokine through observing that infliximab reduces levels of other inflammatory cytokines as well as TNF [22, 23].

The extraordinarily broad relevance of TNF in biology can now be inferred by its strongly conserved state, traceable back through a remarkably ancient lineage including fish and insects, and the TNF receptors on their cells, co-recognizing their human counterparts [24]. Unsurprisingly, therefore, including the brain, has proved to be influenced by this cytokine. By 1987, TNF had been shown to be a necessary part of the chain of events that control normal sleep [25], and a few years later, current conductance in neurons of a sea slug, Aplysia kurodai, was observed to be reduced by human TNF [26, 27]. Next, physiological levels of TNF had been reasoned to be necessary for normal mammalian neuronal function, with a loss or gain of TNF beyond homeostatic limits being pathological [28]. Nevertheless, data on other proinflammatory or anti-inflammatory cytokines such as IL-1β, IL-4, IL-17, and IL-23 [29–31] continue to add to the principles behind this concept and may well generate related therapeutic avenues.

**TNF excess in neurodegenerative states**

Twenty years ago, the involvement of unchecked chronic TNF generation, particularly within the brain, in the pathogenesis of stroke, traumatic brain injury (TBI), and AD began to be apparent [32–34]. Refinements of these scientific arguments have accumulated to the present day [35–41]. The subtle relationship between these cytokines and the brain has been nicely put by noting that even when it appears that the nervous system is succumbing to a flared immune system, and the two systems maintain a constant dialogue in the attempt to restore homeostasis [42].

The rationale for treating chronic neurodegenerative states by reducing excess cerebral TNF extends far beyond the post-stroke syndrome, AD, and TBI noted above. Despite “belonging” to various disciplines, these cerebral states characterized by TNF excess clearly have much pathophysiology in common. They include (Table 1) Parkinson’s disease (PD) [43], neurogenic pain [44–50], Huntington’s disease [51], amyotrophic lateral sclerosis [52], septic encephalopathy [53], defective post-operative cognition [54, 55], defective post-irradiation [56] and post-chemotherapy [57, 58] cognition, defective cognition during RA [48], epileptic seizures [59, 60], viral encephalitides [61], cerebral malaria [62], and HIV dementia [63]. Moreover, recent evidence has very precisely incriminated excess brain TNF in the pathogenesis of AD [64]. The authors employed a novel multivariate regression modeling approach, termed partial least squares regression, to investigate cytokine protein concentrations in brain tissue from AD and control patients. Taking into account the order in which brain regions are known to be impacted during the development of AD, region-specific profiles were used to identify high concentrations of cytokines which, when used alone, killed neurons in vitro. Of the 48 cytokines monitored, only TNF (TNFα in their text) met this condition. This is entirely consistent with the evidence we have previously presented [37] that increased cerebral TNF is the most logical therapeutic target for countering this disease. As we review here, the largely neglected evidence that variation in TNF, through regulating both the release and clearance of cerebral glutamate, seems destined to widen an appreciation of this cytokine within neuroscience as a mediator of plasticity and excitotoxicity.

**Glutamate in brain physiology and pathophysiology**

L-glutamate, the most abundant extracellular amino acid in the brain, is, as reviewed over the decades [65–67], the chief physiological excitatory neurotransmitter, including in normal memory and learning. Cerebral glutamate is formed, in microglia and astrocytes [68], as well as neurons, by glutaminase acting on glutamine, and becomes extracellular. Homeostasis is normally maintained by a balance between this reaction and glutamate re-uptake from the synaptic cleft by a series of transport, or re-uptake, proteins that initiate its recycling.

| Table 1 Association of excess TNF and glutamate in brain in neurodegenerative states. See text for references |
|---------------------------------------------------------------|
| **Disease** | **Excess brain TNF** | **Excess brain glutamate** |
| Alzheimer’s disease | + | + |
| Parkinson’s disease | + | + |
| Huntington’s disease | + | + |
| Amyotrophic lateral sclerosis | + | + |
| Septic encephalopathy | + | + |
| Traumatic brain injury | + | + |
| Stroke | + | + |
| Poor post-operative cognition | + | + |
| Poor post-irradiation cognition | + | + |
| Poor post-chemotherapy cognition | + | ? |
| Poor cognition in rheumatoid arthritis | + | ? |
| Epileptic seizures | + | + |
| HIV dementia | + | + |
| Cerebral malaria | + | + |
| Neurogenic pain | + | + |
| Viral encephalitides | + | + |
back to glutamine. As discussed below, much literature associates TNF with glutamate regulation. Both too much or too little, TNF and glutamate are harmful. In brief, a plausible paired physiological role for them is low fluctuating levels of TNF determining physiological levels of glutamate in hippocampal homeostatic synaptic plasticity [69, 70], as described below.

As reviewed [66, 71], should extracellular cerebral glutamate become excessive, whether through excess release or poor clearance, or both, a harmful excitotoxicity ensues. From the 1990s, understanding the disruptions that can cause this increase has been an intense focus of interest in the pathophysiology of neurodegenerative diseases. These conditions (Table 1) came to include AD [72], PD [73], Huntington’s disease [74], amyotrophic lateral sclerosis [75], stroke [76], viral encephalitides [77, 78], septic encephalopathy [79], defective post-operative cognition [80], post-irradiation brain function [81], pain [82, 83], bacterial meningitis [84], epileptic seizures [85], human immunodeficiency virus (HIV) dementia [86], cerebral malaria [87], and TBI [88–90]. In addition, the key studies of Jourdain and co-workers [91] convincingly combined functional and ultrastructural evidence to argue the case for glutamate from astrocytes being a key player in physiological control of synaptic strength. Increasingly, these glutamate pathways have therefore become essential background reading for those whose chief interest has been developing therapeutic drugs for treating these conditions. A recent comprehensive review [92] provides a clear account of the complexities of the control of cerebral extracellular glutamate in chronic, as distinct from acute, excitotoxicity in neurodegenerative states, and discusses amyotrophic lateral sclerosis (ALS), AD, and Huntington’s disease as examples. However, this text takes no account of the presence of excess cerebral TNF production or its influence on extracellular brain glutamate levels in these and similar diseases [34, 51, 93–95].

The roles of excess cerebral TNF in generating glutamate toxicity

Inhibition of re-uptake proteins

As reviewed in 2001 [96], glutamate re-uptake from the synaptic cleft noted above is controlled by fluctuations in a unique family of amino acid transport, or re-uptake, proteins that act as signal terminators. Their inhibition is intricately involved in the pathogenesis of glutamate-excess excitotoxicity diseases such as stroke, AD, epilepsy, and chronic pain syndromes. Twenty years ago, TNF was first implicated in generating excitotoxicity through its capacity to inhibit glutamate re-uptake in an HIV dementia model [97] and subsequently in cultures brain slices [98] and a Sindbis virus disease model [99]. Although outside the topic of this review, which discusses entry of glutamate into the synaptic cleft rather than its actions while there, we note that emphasis has more recently been placed on the ability of TNF to regulate the various types of glutamate receptors [100]. The details of control of these transport proteins by TNF have more recently been updated in a rat model of ALS [101]. When combined, the ideas generated in these fields of research have allowed insightful functional links of neuroinflammation and glutamate-induced excitotoxicity to be proposed [102, 103].

Glutaminase upregulation

In the event, TNF became much more heavily incriminated in glutamate regulation than has been taken into consideration in the above models of excitotoxicity (Fig. 1). Ten years ago, this cytokine was reported to generate excessive glutamate levels by markedly upregulating glutaminase activity [104]. This was confirmed, as was a concomitant reduction in glutamate re-uptake, in a model of Japanese viral encephalitis [105]. The next year, with the same surprisingly little influence on mainline excitotoxicity research to date, glutaminase upregulation was reported after stimulating primary cultured human neurons with TNF or interleukin-1β [106]. Furthermore, these authors found the glutamate increase to occur in the extracellular space as well as intracellularly. The following year, this group also showed that etanercept reduces inflammation and lethality in the above model of Japanese viral encephalopathy [107]. Clearly, by increasing glutamate production while simultaneously reducing its re-uptake [97], excess TNF can be expected to readily cause glutamate to accumulate to toxic levels. This implies much more therapeutic potential for anti-TNF agents than other drugs possessing only one of these activities, such as 6-diazo-5-oxo-norleucine (DON), ceftriaxone, or riluzole, as discussed below. However, this TNF-glutaminase link, despite first being made a decade ago (above), does not yet appear to be common currency in neurodegenerative disease circles (e.g., [108]). Readers interested in the complexities of glutamate release, including its physiological control, are directed to the examples provided by references [109–111].

In passing, we note that glutamine deficiency is a long-recognized characteristic of chronic inflammatory stress and has made nutritionally motivated i.v. glutamine replacement therapy a routine, if formally untested, adjunct treatment in critical care wards [112]. However, a recent post hoc analysis of a large-scale randomized trial has shown this procedure to be of no value, perhaps even harmful [113]. This raises the possibility that chronic TNF increase present in these patients may have caused the observed glutamine depletion by the combined effects of enhancing its conversion to glutamate, plus inhibiting its reconversion from glutamate, as
summarized above. Clearly, amino acids have many functions as well as providing nutrients.

**Glutamate toxicity as a major manifestation of excess TNF in brain disease**

The above data on TNF provide insights into the breadth of therapeutic relevance of the functional link between unbridled TNF production and glutamate neurotoxicity and how this adds immensely to the central argument of this review that TNF is a highly logical target in neurodegenerate disease. As but one example, the capacity of excess TNF to greatly increase glutamate output through activating glutaminase [104, 105] casts the considerable body of work on astrocytes, glutamate, and basal ganglia excitotoxicity, in which the influence of inflammatory cytokines are not considered [114], in a new light. It also modifies the novel “glutamate grabber” approach to treating brain ischemia [115], in that etanercept is, from the above insights, likely to be much more effective than glutamate-oxaloacetate transaminase or oxaloacetate by preventing an excess of newly formed glutamate.

Importantly, intra-amygdala infusion of TNF has been reported to elevate glutamate levels in this region of the brain [116]. Likewise, etanercept, a specific anti-TNF biological in wide clinical use, lowers brain glutamate levels in experimental models (Table 2). Although etanercept is too large a molecule for all but a small amount of a subcutaneous (s.c.) dose to enter the cerebrospinal fluid (CSF), intentionally compensating for this by giving a 20-fold larger dose reduces brain glutamate in a rat model of traumatic brain injury [117]. Etanercept has also been reported, in a heart failure model in which TNF is increased [118, 119], to lower rat brain glutamate dramatically when given intracerebroventricularly (i.c.v), although, again because of its high molecular weight, not when administered intraperitoneally (i.p.).
Do these actions of TNF explain the rapid response to etanercept in neurodegenerative disease?

Control of glutamate by TNF might also explain why etanercept has often been reported to reverse a number of clinical manifestations of neurodegenerative disease surprisingly rapidly. It was shown 17 years ago [120] that turnover of cerebral extracellular glutamate is very fast, seconds to minutes in these authors’ hands. This is evolutionarily essential because of the key role of this amino acid in the synaptic cleft, where it is responsible for the fast excitatory neurotransmission necessary for the rapid brain responses demanded for survival in the real world. Thus, given the role of TNF to influence both glutaminase and reuptake proteins described earlier, the capacity of intracerebral etanercept to lower brain glutamate, as summarized above [117–119], can be expected to act with somewhat the same degree of rapidity. It seems likely, therefore, that these data rationalize the unexpected but clearly rapid response in case reports and open trials to perispinal etanercept, initially reported in 2003 [121] and 2008 [122], and regularly confirmed since [123–127]. Awareness of this 1999 report on the rapidity of extracellular cerebral glutamate turnover [120] may now help contribute to the body of accruing evidence that should alter attitudes regarding reports of rapid responses to anti-TNF in neurodegenerative disease [126, 128].

Therapeutic implications for excitotoxicity in neurodegeneration

Specific anti-TNF biologicals

Whereas infliximab and adalimumab are essentially monoclonal antibodies directed at TNF itself, etanercept, the only anti-TNF biological drug yet tested in this context, is a fusion protein consisting of the p75 TNF receptor, joined to the constant end of the IgG1 antibody [129]. An etanercept biosimilar is already in the literature [130, 131], and a number of others already have approval or are being developed [132], providing the prospect of reduced treatment costs for most of the world. Recent debates on competitive pressures versus scientific rationales delaying introduction of biological biosimilars are most informative [133]. Clearly, regulating this field is a state of flux.

The use of anti-TNF agents in neurodegenerative disease has its critics who largely base their concerns on whether the functional complexities of TNF science, such as the p55 and p75 TNF receptors and membrane versus soluble location of TNF, should be more fully elucidated beforehand [134, 135]. This is largely overplayed: clinical development of the specific anti-TNF biologicals

| Excess cerebral TNF present | Positive outcome after etanercept, etc. | Positive non-specific TNF inhibitors outcome |
|-----------------------------|----------------------------------------|--------------------------------------------|
|                             | Thalid or dithio-thalid | Nilotinib | Cannabinoids |
| Alzheimer’s disease         | +                        | +     | +             |
| Parkinson’s disease         | +                        | ?     | +             |
| Huntington’s disease        | +                        | ?     | ?             |
| Amyotrophic lateral sclerosis | +                       | +     | ?             |
| Septic encephalopathy       | +                        | ?     | ?             |
| Traumatic brain injury      | +                        | +     | ?             |
| Stroke                      | +                        | +     | ?             |
| Poor post-operative cognition | +                      | +     | ?             |
| Poor post-chemother cognition | +                     | ?     | ?             |
| Poor post-irradiation cognition | +                  | ?     | ?             |
| Epileptic seizures          | +                        | ?     | ?             |
| HIV dementia                | +                        | ?     | ?             |
| Neurogenic pain             | +                        | +     | ?             |
| Viral encephalitides        | +                        | ?     | ?             |
| Elevated brain glutamate    | +                        | +     | ?             |
| Lower brain glutamate       | +                        | +     | ?             |
in RA, psoriasis, and Crohn’s disease went ahead successfully during the past decades alongside continuing yet incomplete basic research without such reservations being aired. The case for cautious use of specific biological anti-TNF agents based on the soundness of the pathophysiological arguments in otherwise untreated conditions, with an eye to potential concerns, has been amply made in systemic states [136]. In practice, the balance of safety versus outcomes has proved to be very much on the side of the millions of patients who have received regular treatment with these agents for many years now.

**Blood-brain barrier (BBB) passage by specific anti-TNF biologicals**

As other therapeutic molecules, the biological anti-TNF agent etanercept, though employed widely with great success systemically, is, as often noted, too large to cross the BBB in significant amounts unaided. Two BBB-crossing techniques now exist side by side in the literature, the earliest and simplest from a small group, the later technically complex, and not yet tried in patients. Here, we summarize their origins and rationale.

**Perispinal delivery of etanercept**

Understanding the perispinal delivery of large molecular weight drugs into the central nervous system requires an appreciation of the cerebrospinal venous system. As recently reviewed in detail [137], this route of cerebral venous drainage has had, since its discovery well over a century and a half ago, a most complex and interesting history, and more recently application, in medical advances. Contemporary awareness of the potential of this route began when researchers in aviation medicine were exploring an animal model of the effects of gravity and body position on pilots of high-performance aircraft [138]. They noted that restraining anesthetized rabbits on a tilt board and rotating them to a head-down position considerably increased CSF levels of the plasma protein albumin within 5 min. The authors noted, in passing, that as well as aiding their branch of science, their data had implications for getting large molecular weight therapeutics into the brain. As discussed [139, 140], the principle behind this approach—drug delivery to the brain by retrograde venous flow—began to be used off-label the early 2000s to get etanercept into the brain in patients with neurogenic pain [121] and AD [141]. Although these open trial observations (Table 2) continue to be reported post-stroke [125] and TBI [125], and the principles they embrace now have a solid foundation in animal models [50, 55, 142–144], remarkably they have not, as did parallels in inflammatory states in other organs earlier, attracted funding for randomized human trials. As noted above, a wider awareness of the rapid rate of glutamine to glutamate kinetics [120] may well, through rationalizing the reported rapid response [121, 122], reduce skepticism.

**Trojan Horse delivery of etanercept**

An alternative method of delivery of large molecules into the brain exists [145–147], but it ignores the above input from aviation medicine and, as has been discussed [148–150], remains fraught with technical difficulties. In 2011, the UCLA/Armagen group reported that a re-engineered version of etanercept, in which the IgG part of the fusion protein is a chimeric monoclonal antibody against the mouse transferrin receptor, could be delivered into the mouse brain in this way [151]. The following year, they reported that this re-engineered etanercept reduced the harmful effects of experimental stroke in a mouse model [152]. It cannot, however, be tested in humans until etanercept is re-engineered so that it recognized human, as distinct from mouse, transferrin. Moreover, re-engineering is essential for each large molecule under consideration, whereas they can be expected to function in their original form when introduced perispinally. A recent review [153] discusses a number of further complexities that need addressing before Trojan Horse delivery could become routinely used.

**Non-specific inhibitors of TNF**

**3,6 Dithio-thalidomides**

Thirty years after being removed from the market in 1961 because of its disastrous effects on fetal development, thalidomide had begun to be explored to treat a number of intractable conditions in patients other than child-bearing age women. It was shown to selectively inhibit TNF production by stimulated human monocytes [154], and to do so by enhancing degradation of the mRNA for this cytokine [155]. A decade later, a series of thio-thalidomides with higher anti-TNF effects than the parent compound were synthesized [156], and the outcomes of their use on TNF mRNA generation closely compared [157]. A considerable literature now exists on some compounds of this class, which are orally active, pass the blood-brain barrier (BBB) and improve outcome in neurodegenerative disease models by inhibiting TNF. They are widely efficacious, by various behavioral and cognitive criteria, in models of lipopolysaccharide-induced neuroinflammation [158], AD [159–161], TBI [55], and stroke [142]. Recently, the parent compound has been reported to reduce a form of neurogenic pain by repressing the inflammatory response [162]. We are unaware of any literature on dithio-thalidomides influencing glutaminase, but the parent compound also has been reported to prevent hypoxia-induced TNF from inhibiting one of the glutamate re-uptake proteins [163].
Nilotinib
Nilotinib, a tyrosine kinase inhibitor, is 30 times more potent than imatinib, which it is replacing for treating certain leukemias [164, 165]. A small open trial of 6-month duration performed at Georgetown University Hospital was reported at the most recent Annual Meeting of the American Society for Neuroscience. Daily oral nilotinib showed promise, in an initial uncontrolled trial, of reversing clinical aspects of PD with or without dementia, as well Lewy Body dementia [166]. Phosphorylated tau (P-tau), α-synuclein, and Aβ were noted to have been significantly reduced [166] in nilotinib-treated patients. Previously, nilotinib had been reported, by this group and others, to be successful in controlled studies in mouse PD models [167–169]. One of these groups [169] demonstrated that a clinically useful proportion of orally administered nilotinib, as used in this new open trial [166], passes through the BBB. Prior animal studies also show that using nilotinib and the closely related dasatinib was useful in models of AD [170–172].

The capacity of nilotinib (and indeed dasatinib [170]) to inhibit TNF generation in vivo [173, 174], and the observations that blocking TNF duplicates this effect of nilotinib in PD models [43, 175], appear to have not yet been considered as a plausible mechanism of these new clinical observations with this agent [166]. Nevertheless, as an anti-TNF agent, nilotinib can be expected, from the activity of TNF in these contexts [97, 104], to inhibit glutaminase activity as well as enhance glutamate reuptake proteins. In addition to nilotinib [176] another selective Src tyrosine kinase, pyrazolopyrimidine-2 (PP-2), inhibits production of TNF [177]. Also, given that insulin resistance is a common direct consequence of chronically increased TNF [178], further evidence for anti-TNF effects being central to these observations with nilotinib comes from the ability of these tyrosine kinase inhibitors to treat type 2 diabetes mellitus (T2DM) by decreasing insulin resistance [179].

How might nilotinib reduce TNF levels? Tyrosine phosphorylation is central to TLR stimulation and subsequent activation of NF-kappaB [180] that generates cytokines such as TNF. Endotoxin tolerance is associated with inhibited phosphorylation Src, a non-receptor tyrosine kinase protein [181]. It is therefore plausible that agents such as nilotinib, which inhibit Srcs, reduce TNF production [173, 174] by mimicking tolerance to TLR agonists such as endotoxin.

Cannabinoids
As reviewed [182], the therapeutic and pharmacological secrets of Cannabis sativa have fascinated researchers for about two centuries. About 90 phytocannabinoids (i.e., compounds present in the plant) have been identified, the two with the largest literatures being tetrahydrocannabinol (THC) and cannabidiol (CBD). The former is psychoactive and thus under a legal cloud, although a synthetic trans-9-delta isomer, termed dronabinol, is an example of forms of THC nowadays undergoing limited investigation [183]. CBD, in contrast, does not cause significant behavioral change and is researched much more widely. These phytocannabinoids, self-evidently BBB permeable, proved to be ligands for two previously unsuspected receptors, mainly found on cells of the immune system, and whose presence led to the prediction and discovery of endogenous cannabinoids, or endocannabinoids. In physiological terms, these may be considered as part neurotransmitter, part cytokine, and part hormone and have been identified and studied at length (see [184, 185] for reviews.)

Both endocannabinoids and CBD have been shown to be active in models for pain [186–190], AD [191–195], epileptic seizures [196–199], PD [200–202], HIV dementia [203–205], viral encephalitis [206], and TBI [207]. Clearly, this list parallels the conditions, discussed earlier, with which excessive cerebral levels of TNF are associated. These agents are also active in hypoxic encephalopathy, a stroke parallel in newborns [208, 209], a condition associated with raised inflammatory cytokines and glutamate [210]. Not surprisingly, therefore, cannabinoids, whether synthetic, endogenous, or of plant origin, have proven to be established anti-TNF agents in vitro and in vivo, in the sense that they reduce its production by the usual recognized stimuli [211–214]. This list includes treating the murine malarial encephalopathy (cerebral malaria) [214], a condition in which, as discussed below, 6-diazo-5-oxo-norleucine is also efficacious for a related and predictable reason concerned with lowering extracellular cerebral glutamate [215].

Again, the list of model conditions investigated for therapeutic use of cannabinoids in the previous paragraph remarkably mirrors the list of previously discussed conditions associated with excessive cerebral extracellular levels of glutamate. Moreover, treatment with cannabinoids or altering the function of their cellular receptors [185, 191, 216–221] has been reported to lower the levels, or function, of brain glutamate (Table 2). This is entirely consistent with their activity as anti-TNF agents [211–214].

Agents that do not influence TNF but still reduce extracellular brain glutamate
6-Diazo-5-oxo-norleucine (DON), a glutaminase inhibitor DON, a glutamine analogue, is studied largely with a view to reduce extracellular glutamate, and thus treat glutamate toxicity, through inhibiting glutaminase. Having been earlier shown [222] to possess anti-tumor properties, nearly 40 years later, DON was reported to inhibit glutaminase and thus reduce the release of glutamate in the rat cerebral cortex [223]. Through the last decade,
DON has been a useful, albeit often toxic [224], experimental tool to demonstrate that glutamate-mediated excitotoxicity is a significant component of the pathogenesis of various neurodegenerative states, including brain ischemia [225]. Cerebral glutamate homeostasis is disrupted in mouse models of both the neurological sequelae of Sindbis virus infection [226] and malarial encephalopathy caused by Plasmodium berghei ANKA [87], and DON has been successfully used therapeutically in experimental versions of both conditions [215, 227]. It has also been useful in an in vitro HIV dementia model [228] and in both in vitro and ex vivo experimental autoimmune encephalitis, a mouse model of multiple sclerosis [229].

These new data on DON and the relationship between TNF and glutamate excess through glutaminase enhancement put historic observations on malarial encephalopathy into clearer focus. As has been reviewed [17], malaria was the first disease, infectious or otherwise, for which TNF was argued to be central to its pathogenesis, and it set the pattern for the rest. Yet a large trial of a specific anti-TNF antibody, injected intravenously, failed to show evidence, in a large trial in West Africa, of any protective effect in children with cerebral malaria [230]. At that time, however, ideas on malarial disease were predicated on harmful levels of TNF being produced intravascularly, where the parasites that stimulate its production reside, so it was considered logical to administer the antibody into this compartment. Not until 8 years ago was the excess TNF in cerebral malaria shown to originate in the brain [62]. These authors predicted that interventions to decrease TNF production in the brain might be required in order to improve outcomes. Thus, treating human cerebral malaria with perispinal etanercept, evidently an equivalent to administering it i.c.v. [125], will have at least as good and theoretically better ability—since it would also enhance re-uptake proteins—as DON to reduce excessive levels of glutamate, and therefore improving clinical outcome. DON, a molecule not known to affect re-uptake proteins, but which inhibits glutaminase [223], as well as passes the BBB when given i.p. [231], has recently also been effective in treating mice infected with Sindbis virus [227] as well as the cerebral malaria model discussed above [215].

Ceftriaxone and riluzole, glutamate re-uptake transporter enhancers
Ceftriaxone is a broad-spectrum beta-lactam antibiotic, largely reserved, in this context, for use against otherwise resistant bacteria. In contrast to cannabinoids and nilotinib, it has been shown not to reduce TNF release from LPS-treated human monocytes [232], implying it does not act against excitotoxicity by inhibiting TNF-mediated glutaminase enhancement [97] or enhancing TNF-mediated reduced glutamate re-uptake [104]. In 2007, ceftriaxone was shown to independently enhance glutamate re-uptake and thus reduce the glutamate-dependent portion of morphine-dependent hyperthermia [233]. This activity of ceftriaxone was soon shown, in primary fetal human astrocytes, to operate through increased expression of excitatory amino acid transporter 2 (EAAT2) promoter activity, allowing it to inhibit glutamate-induced excitotoxicity of its own accord [234]. As these authors noted, this implies that ceftriaxone could have therapeutic activity in a range of neurodegenerative conditions, essentially the examples we discussed earlier as exhibiting excitotoxicity. With this mechanism in mind, ceftriaxone is nowadays under active consideration as a therapy in models of AD [235], stroke [236], TBI [237–239], and PD [240–243]. The most complete evidence consistent with this approach to date is a very recent extensive report on ceftriaxone rescuing brain function in Toxoplasma gondii-infected mice [244]. The authors documented high brain glutamate, although how this arose remains uncertain. T. gondii is a well-known TNF inducer. Being a pathogen, it possesses the PAMP activity discussed earlier.

Riluzole (6-(trifluoromethoxy)benzothiazol-2-amine), a relatively toxic material nevertheless approved for treatment of ALS, has for some time been known to be a glutamate release inhibitor and thus affecting the glutamate functions discussed above. This has been reported to include enhancing levels of glutamate re-uptake transporters [245], including in astrocytes [246, 247]. This principle is entirely consistent with findings in a mouse AD model [248] and has been extended in a recent study in which riluzole proved to reverse the same array of human gene changes in AD and aging [249]. Both research groups suggest the effects of riluzole as a possible mechanism underlying its improvement in cognitive function in their studies.

Relative effectiveness of these treatments
As discussed earlier, neurodegenerative diseases are characterized by excessive levels of extracellular cerebral glutamate that can be expected to have accumulated through its too rapid formation as well as its slowed re-uptake and conversion back to glutamine. The ideal therapy would be able to reverse both of these changes. So far as we are aware, TNF is the only endogenous mediator that, when in excess, as in the brain in these diseases, enhances cerebral glutaminase [104] and also inhibits glutamate re-uptake proteins [97]. Since anti-TNF agents, both specific and non-specific, can be predicted to simultaneously reverse both of these TNF-induced changes, their efficacy in reversing this excitotoxicity can be expected, from first principles, to be higher than agent such as DON, ceftriaxone, or riluzole, which correct only one of these two pathways.
Specific anti-TNF biologicals are expensive, but can be very effective through neutralizing a precise target, in this case excessive cerebral TNF, known to be central to the disease in question. As discussed earlier, their large size need not be a problem. In contrast, pharmaceuticals such as dithio-thalidomides, nilotinib, cannabinoids, DON, ceftriaxone, and riluzole, although less expensive, may prove to be burdened with unknown targets that generate greater side effects than anti-TNF biologicals can. They have, however, a considerable advantage in neurodegenerative disease in that when administered orally or systemically, they can traverse the BBB and get to where they are needed [143, 157, 169, 231].

Conclusions
We propose that the excess levels of TNF, and glutamate in the brain across a range of neurodegenerative diseases are crucially linked, high TNF causing extracellular glutamate to accumulate to levels high enough to inhibit synaptic activity and kill neurons by two synergistic mechanisms. As described, these are increasing glutamate production by enhancing glutaminase and simultaneously reducing glutamate clearance by inhibiting re-uptake proteins, thus causing it to accumulate in the synaptic cleft. The shared efficacy of specific anti-TNF biologicals and non-specific anti-TNF agents (thio-thalidomides, nilotinib and cannabinoids) on this superficially diverse range of conditions can thus be understood. The usefulness of DON, ceftriaxone, and riluzole, agents without apparent anti-TNF activity, but each possessing separate activities that counter one of these two influences of high TNF on glutamate accumulation, are similarly rationalized.

Acknowledgements
The authors are most grateful to Sharyn Wragg for the artwork in Fig. 1. The authors have no conflicts of interest that are relevant to the content of this article.

Funding
This research was supported by the National Health and Medical Research Council (NHMRC) of Australia via research project grant #1083569, Iain S. Gray in memory of Kylee, the Roth family Foundation, and the Boyarsky family. The funders had no role in the content of the text, decision to publish, or preparation of the manuscript.

Availability of data and materials
Not applicable.

Authors’ contributions
IAC proposed the scope of the review. Both authors were involved in planning and editing the manuscript, blending their complementary expertise. Both authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Not applicable.

References
1. Lee HG, Zhu X, Castellani RJ, Nunomura A, Perry G, Smith MA. Amyloid-beta in Alzheimer disease: the null versus the alternate hypotheses. J Pharmacol Exp Ther. 2007;321:823–9.
2. Castellani RJ, Zhu X, Lee HG, Smith MA, Perry G. Molecular pathogenesis of Alzheimer’s disease: reductionist versus expansionist approaches. Int J Mol Sci. 2009;10:1386–406.
3. Mullane K, Williams M. Alzheimer’s therapeutic: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond? Biochem Pharmacol. 2013;85:289–305.
4. Castello MA, Jeppson JD, Soriano S. Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer’s disease. BMC Neurol. 2014;14:169.
5. Morris GP, Clark IA, Vissel B. Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer’s disease. Acta Neuropathol Commun. 2014;2:135.
6. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsovelas ND, Ziolko SK, James JA, Snitz BE, Hoock PR, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65:1509–17.
7. Rowe CC, Ellis KA, Rimajoya M, Bourgeat P, Pike KE, Jones G, Fripp J, Tochen Danguy H, Morandieu L, O’Keeffe G, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31:1275–83.
8. Chou RC, Kane M, Ghimire S, Gautam S, Gui J. Treatment for rheumatoid arthritis and risk of Alzheimer’s disease: a nested case-control analysis. CNS Drugs. 2016.
9. Clark IA, Vissel B. Amyloid-beta one of three danger-associated molecules that are secondary inducers of the proinflammatory cytokines that mediate Alzheimer’s disease. Br J Pharmacol. 2015;172:3174–27.
10. Izhaki RF, Lathe R, Balin BJ, Ball MJ, Beare EL, Braak H, Bullido MJ, Carter C, Cenic M, Cosby S, et al. Microbes and Alzheimer’s disease. J Alzheimers Dis. 2016;51:979-84.
11. Rowan MJ, Kyubin I, Wang Q, Hu NW, Arwyl RP. Synaptic memory mechanisms: Alzheimer’s disease amyloid beta-peptide-induced dysfunction. Biochem Soc Trans. 2007;35:1219–23.
12. Salloway S, Sperling R, Fox NC, Blennow K, Kunkl W, Raskind M, Sapp M, Honig LS, Porsteinsson AP, Ferris S, et al. Three phase trials of taupeinumbuzam in mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370:222–33.
13. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishiti MA, Home P, Heslin D, French J, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer’s disease. Nature. 2000;408:979–82.
14. Butchart J, Brook L, Hopkins V, Teeling J, Puntener U, Culliford D, Sharples R, Sharif S, McFarlane B, Raybould R, et al. Etaeceptor in Alzheimer disease: a randomized, placebo-controlled, double-blind, phase 2 trial. Neurology. 2015;84:2161–8.
15. Canswell EA, Old LJ, Kassel RL, Green S, Fiore N, Willamson B. An endotosin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 1975;72:3666–70.
16. Clark IA, Virelizier J-L, Canswell EA, Wood PR. Possible importance of macrophage-derived mediators in acute malaria. Infect Immunity. 1988;53:1058–66.
17. Clark IA, Alleva LE, Mills AC, Cowden WB. Pathogenesis of malaria and clinically similar conditions. Clin Microbiol Rev. 2004;17:509–39.
18. Tovey MG. The expression of cytokines in the organs of normal individuals: role in homeostasis. A review. J Biol Regul Homeost Agents. 1988;2:87–92.
19. Marano MA, Molawer LL, Fong Y, Wei H, Minei J, Yurt R, Cerami A, Lowry SF, Cachectin/TNF production in experimental burns and Pseudomonas infection. Arch Surg. 1988;123:1383–8.
20. Navroth PP, Bank I, Handley D, Casimires J, Chess L, Stern D. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J Exp Med. 1986;163:1363–75.
21. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Brevedfeld FC, Macfaldane JD, Billing H, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (c2A) versus placebo in rheumatoid arthritis. Lancet. 1994;344:1105–10.
22. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet. 1989;2:244–7.
23. Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, Brevedfeld FC, Smolen JS, Ebel G, deBoode K, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol. 1999;163:1521–8.
24. Quistad SG, Stotland A, Barott KL, Smurthwaite CA, Hilton BJ, Grasis JA, Benson JM, Sachs CW, Treacy G, Zhou H, Pendley CE, Brodmerkel CM, Ignatowski TA, Spengler RN. Tumor necrosis factor-alpha: presynaptic modulation of transmitter release. J Neurosci. 1991;28:466–73.
25. Ignatowski TA, Spengler RN. Tumor necrosis factor-alpha presynaptic sensitivity is modified after antidepressant drug administration. Brain Res. 1994;665:293–9.
26. Gadani SP, Cronk JC, Norris GT, Kipnis J. IL-4 in the brain: a cytokine to remember. J Immunol. 2012;189:213–9.
27. Benson JM, Sachs CW, Treacy G, Zhou H, Penderly CE, Brodmelken CM, Shankar G, Maselli MA. Therapeutic targeting of the IL-12/23 pathway: generation and characterization of ustekinumab. Nat Biotechnol. 2011;29:615–20.
28. Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, Barlow M, Lysko PG, Arvin B, Neville LF, Barone FC, Feuerstein GZ. The role of inflammation and cytokines in brain injury. Neurosci Biobehav Rev. 1996;20:445–57.
29. Shoham S, Davenne D, Cady AB, Dinarello CA, Krueger JM. Recombinant tumor necrosis factor and interleukin-1 enhance slow-wave sleep. Am J Physiol. 1987;253:R142–9.
30. Sawada M, Hara N, Maeno T. Extracellular tumor necrosis factor induces a decreased K+ conductance in an identified neuron of Aplysia kurodai. J Neurophysiol. 1999;82:2663–70.
31. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, Mcclanahan T, Kastelein RA, Cua DJ. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201:233–40.
32. Sawada M, Hara N, Maeno T. Analysis of a decreased Na+ conductance by a tumor necrosis factor in identified neurons of Aplysia kurodai. J Neurosci. 1999;19:802–7.
33. Ignatowski TA, Spengler RN. Tumor necrosis factor-alpha drives Alzheimer disease. Pharmacol Ther. 2010;128:519–30.
34. Barone FC, Arvin B, White RF, Miller A, Webb CL, Willette RN, Lysko PG, Arvin B, Neville LF, Barone FC, Feuerstein GZ. The role of inflammation and cytokines in brain injury. Neurosci Biobehav Rev. 1996;20:445–57.
cytokines by profiling Alzheimer’s disease tissues and neuron culture viability screening. Sci Rep. 2015;5:16622.

65. McIntee WJ, Crook TH. Glutamate: its role in learning, memory, and the aging brain. Psychopharmacology (Berl). 1993;111:391–401.

66. Thomas RJ. Excitatory amino acids in health and disease. J Am Geriatr Soc. 1995;43:1279–89.

67. Zhou Y, Danbolt NC. Glutamate as a neurotransmitter in the healthy brain. J Neural Transm (Vienna). 2014;121:799–817.

68. Bezi P, Domercq M, Brambilla L, Galli R, Scholz D, De Clercq E, Vescovi A, Bagetta G, Kollars G, Moldesji J, Volterra A. CXCR4-activated astrocyte glutamate release via TNFalpha amplification by microglia triggers neurotoxicity. Nat Neurosci. 2001;4:702–10.

69. Albenis BC, Mattson MP. Evidence for the involvement of TNF and NF-kappaB in hippocampal synaptic plasticity. Synapse. 2000;35:151–9.

70. Bonansco C, Couve A, Perea G, Ferradas CA, Roncagliolo M, Fuenzalida M. Glutamate released spontaneously from astrocytes sets the threshold for synaptic plasticity. Eur J Neurosci. 2011;33:1483–92.

71. Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron. 1980;10:23–34.

72. Mulli DE, Norwell DY, Schwartz FN. Plasma concentrations of glutamate and its metabolites in patients with Alzheimer’s disease. J Am Osteopath Assoc. 1993;93:670–7.

73. Loschmann PA, Lange KW, Wachtel H, Turski L. MPTP-induced degeneration: interference with glutamatergic toxicity. J Neural Transm Suppl. 1994;43:133–43.

74. Behrens PF, Franz P, Woodward B, Lindenberg KS, Landwehrmeyer GB. Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. Brain. 2002;125:1908–22.

75. Spekre-Yaroquas O, Bensimon G, Lacomblez L, Salachas F, Pradat PF, Le Forestier N, Marouan A, Dib M, Meininger V. Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. J Neurol Sci. 2002;203:73–8.

76. Berneniste H, Drejer J, Schouboe A, Diemer NH. A comparison of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischaemia monitored by intracerebral microdialysis. J Neurochem. 1984;43:1369–74.

77. Nagi-Auzenm JL, Griffin DE. Sindbis virus-induced neuronal death is both necrotic and apoptotic and is ameliorated by N-methyl-D-aspartate receptor antagonists. J Virol. 2001;75:1414–21.

78. Darman J, Backovic S, Dike S, Maragakis NJ, Krishnan C, Rothstein JD, Nargi-Aizenman JL, Griffin DE. Sindbis virus-induced neuronal death is both autonomous and involves glutamate excitotoxicity. J Neurosci. 2004;24:6702–11.

79. Thomas RJ. Glutamate neurotoxicity in health and disease. J Am Geriatr Soc. 2009;57:626–29.

80. Li Y, Wang S, Ran K, Hu Z, Liu Z, Duan K. Differential hippocampal protein expression and late term of sepsis in rats. J Surg Res. 2009;152:238–43.

81. McEntee WJ, Crook TH. Glutamate: its role in learning, memory, and the aging brain. Psychopharmacology (Berl). 1993;111:391–401.

82. Ferrarese C, Aliprandi A, Tremolizzo L, Stanzani L, De Micheli A, Dolara A, Fratalla L. Increased glutamate in CSF and plasma of patients with HIV dementia. Neurology. 2001;57:671–5.

83. Miranda AS, Vieira LB, Lacerda-Queiroz N, Souza AH, Rodrigues DH, Vilela MC, Gomez MV, Machado FS, Rachid MA, Teixeira AL. Increased levels of glutamate in the central nervous system are associated with behavioral symptoms in experimental malaria. Braz J Med Biol Res. 2010;43:1173–7.

84. Spranger M, Schwab S, Krempien S, Winterholler M, Steiner T, Hacke W. Gene expression profile of the glutamate transporter activator (R)-(-)-5-methyl-1-nicotinoyl-2-pyrazoline (MS-153) following traumatic brain injury in the adult rat. J Neurotrauma. 2015, in press.

85. Darman J, Backovic S, Dike S, Maragakis NJ, Krishnan C, Rothstein JD, Nargi-Aizenman JL, Griffin DE. Sindbis virus-induced neuronal death is both necrotic and apoptotic and is ameliorated by N-methyl-D-aspartate receptor antagonists. J Virol. 2001;75:1414–21.

86. Ferrarese C, Aliprandi A, Tremolizzo L, Stanzani L, De Micheli A, Dolara A, Fratalla L. Increased glutamate in CSF and plasma of patients with HIV dementia. Neurology. 2001;57:671–5.

87. Miranda AS, Vieira LB, Lacerda-Queiroz N, Souza AH, Rodrigues DH, Vilela MC, Gomez MV, Machado FS, Rachid MA, Teixeira AL. Increased levels of glutamate in the central nervous system are associated with behavioral symptoms in experimental malaria. Braz J Med Biol Res. 2010;43:1173–7.
111. Santos MS, Li H, Vogtmaier SM. Synaptic vesicle protein trafficking at the glutamate synapse. Neuroscience. 2009;158:189–203.

112. Weitzel LR, Wischmeyer PE. Glutamine in critical illness: the time has come, the time is now. Crit Care Clin. 2010;26:515–25. ix-x.

113. Heyland DK, Elgie K, Cook D, Berger MM, Wischmeyer PE, Albert M, Muscedere J, Jones G, Day AG. Glutamine and antioxidants in the critically ill patient: a post hoc analysis of a large-scale randomized trial. JPEN J Parenter Enteral Nutr. 2015;39:401–9.

114. Morales J, Rodriguez M. Self-induced accumulation of glutamate in striatal astrocytes and basal ganglia excitotoxicity. Glia. 2012;60:1481–94.

115. Castillo J, Loza MI, Mirelman D, Brea J, Blanco M, Sobrino T, Campos F. A novel mechanism of neuroprotection: blood glutamate grabber. J Cereb Blood Flow Metab. 2015;36:292–301.

116. Jing H, Hao Y, Bi Q, Zhang J, Yang P. Intra-amygdala microinjection of TNF-alpha impairs the auditory fear conditioning of rats via glutamate toxicity. Neurosci Res. 2015;91:34–40.

117. Chio CC, Lin JW, Chang MW, Wang CC, Yang CZ, Chang CP. Therapeutic evaluation of etanercept in a model of traumatic brain injury. J Neurochem. 2010;115:921–9.

118. Kang YM, He RL, Yang LM, Qin DN, Guggilam A, Elks C, Yan N, Guo Z, Francis J. Brain tumour necrosis factor-alpha modulates neurotransmitters in hypothalamic paraventricular nucleus in heart failure. Cardiovasc Res. 2009;83:737–46.

119. Kang YM, Wang Y, Yang LM, Elks C, Cardinale J, Yu XJ, Zhao XF, Zhang J, Zhang LH, Yang ZW, Francis J. TNF-alpha in hypothalamic paraventricular nucleus contributes to sympathoexcitation in heart failure by modulating AT1 receptor and neurotransmitters. Tohoku J Exp Med. 2010;222:251–63.

120. Jabaoudon D, Shimamoto K, Yasuda-Kamatani Y, Scanzani M, Gahwiller BH, Gerber U. Inhibition of uptake unmask rapid extracellular turnover of glutamate of nonvesicular origin. Proc Natl Acad Sci U S A. 1999;96:8733–8.

121. Tobinick EL, Brichts-Davodifirad S. Perisinal TNF-alpha inhibition for discogenic pain. Swiss Med Wkly. 2003;133:170–7.

122. Tobinick EL, Gross H. Rapid cognitive improvement in Alzheimer disease following perisinal etanercept administration. J Neuroinflammation. 2008;5:2.

123. Griffin WS. Perisinal etanercept: potential as an Alzheimer therapeutic. J Neuroinflammation. 2008;5:3.

124. Tobinick E. Rapid improvement of chronic stroke deficits after perisinal etanercept: three consecutive cases. CNS Drugs. 2011;25:145–55.

125. Tobinick E, Kim NM, Reyzin G, Rodriguez-Romanacce H, DePuy V. Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perisinal etanercept. CNS Drugs. 2012;26:1051–70.

126. Ignatowski TA, Spengler RN, Dhandapani KM, Folkersma H, Butterworth RF, Baranauskaite A, Tseluyko V, Zhdan VM, Stasiuk B, Milasiene R, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept in Alzheimer disease: a 6-month pilot study. Medscape Gen Med Neurol Neurosurg. 2006;25.

127. Ignatowski TA, Gross H, Weinberger A, Cohen H. TNF-alpha modulation for treatment of Alzheimer’s disease: a 6-month pilot study. Medscape Gen Med Neurol Neurosurg. 2006;25.

128. Yoon JS, Lee JH, Tweedie D, Mughal MR, Chigurupati S, Greig NH, Mattson MP. 3,6-dithiothalidomide improves experimental stroke outcome by suppressing neuroinflammation. J Neurosci Res. 2013;91:571–80.

129. Cabral GA, Jameson M. Marijuana use and brain immune mechanisms. Int Rev Neurobiol. 2014;118:199–230.

130. Tobinick EL, Gross H, Weinberger A, Cohen H. TNF-alpha modulation for treatment of Alzheimer’s disease. Curr Opin Psychiatry. 2015;28:148–54.

131. Baeten D, van Hagen PM. Use of TNF blockers and other targeted therapies in rare refractory immune-mediated inflammatory diseases: evidence-based or rational? Ann Rheum Dis. 2010;69:2667–73.

132. Tobinick EL. Perisinal delivery of CNS drugs. CNS Drugs. 2016;30:469–80.

133. Wen TS, Randall DC, Zolman JF. Protein accumulation in cerebrospinal fluid during –90 degrees head-down tilt in rabbit. J Appl Physiol. 1994;77:1081–6.

134. Probert L. TNF and its receptors in the CNS: The essential, the desirable and the deleterious effects. Neuroscience. 2015;302:22–22.
factor-alpha synthesis inhibitor 3,6-dithiothalidomide attenuates markers of inflammation. Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer’s disease. J Neuroinflammation. 2012;9:106.

169. Karuppagounder SS, Brahmachari S, Lee Y, Dawson VL, Dawson TM, Ko HS. Dhawan G, Floden AM, Combs CK. Amyloid-beta oligomers stimulate Tanabe A, Yamamura Y, Kasahara J, Morigaki R, Kaji R, Goto S. A novel Pagan F. Society for Neuroscience (SfN) 2015 Annual Meeting. Abstract 12. El-Agamy DS. Nilotinib ameliorates lipopolysaccharide-induced acute lung Ocuin LM, Zeng S, Cavnar MJ, Sorenson EC, Bamboat ZM, Greer JB, Kim TS, – 2014;92:373–86.

171. Gabbita SP, Srivastava MK, Eslami P, Johnson MF, Kobrzt NK, Tweedie D, Gei§ NH, Zemlan FP, Sharma SP, Harris-White ME. Early intervention with a small molecule inhibitor for tumor necrosis factor-alpha prevents cognitive deficits in a triple transgenic mouse model of Alzheimer’s disease. J Neuroinflammation. 2012;9:99.

166. Breccia M, Alimena G. Nilotinib: a second-generation tyrosine kinase inhibitor AMN107 (nilotinib) normalizes striatal motor behavior via autophagic degradation of alpha-synuclein in Parkinson’s disease models. Hum Mol Genet. 2013;22:3135–28.

160. Gabbita SP, Srivastava MK, Eslami P, Johnson MF, Kobritz NK, Tweedie D, Boycott HE, Wilkinson JA, Boyle JP, Pearson HA, Peers C. Differential involvement of TNF alpha in hypoxic suppression of astrocyte glutamate transporters. Glia. 2008;56:998–1004.

161. Russo I, Caracciolo L, Tweedie D, Choi SH, Greig NH, Barlati S, Bosetti F. 3,6- Dithiothalidomide, a new TNF-alpha synthesis inhibitor, attenuates the effect of Abeta1-42 intracerebroventricular injection on hippocampal neurogenesis and memory deficit. J Neurochem. 2012;118:1181–92.

162. Song T, Ma X, Gu K, Yang Y, Yang L, Ma P, Wang W, Zhao J, Yan R, Guan J, et al. Thalidomide represses inflammatory response and reduces radiculopathic pain by inhibiting IRAK-1 and NF-kappaB/p38/JNK signaling. J Neuroimmunol. 2016;301:1–8.

163. Maekawa T, Ashihara E, Kimura S. The Bcr-Abl tyrosine kinase inhibitor – 2014;8:50.

164. Maekawa T, Ashihara E, Kimura S. The Bcr-Abl tyrosine kinase inhibitor – 2014;92:373–86.

165. Breccia M, Alimena G. Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia. Leuk Res. 2010;34:129–34.

164. Maekawa T, Ashihara E, Kimura S. The Bcr-Abl tyrosine kinase inhibitor AMN107 (nilotinib) normalizes striatal motor behaviors in a mouse model of Parkinson’s disease. Front Cell Neurosci. 2014;8:50.

165. Breccia M, Alimena G. Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia. Leuk Res. 2010;34:129–34.

166. Pagan F. Society for Neuroscience (SfN) 2015 Annual Meeting. Abstract 12. El-Agamy DS. Nilotinib ameliorates lipopolysaccharide-induced acute lung Ocuin LM, Zeng S, Cavnar MJ, Sorenson EC, Bamboat ZM, Greer JB, Kim TS, – 2014;92:373–86.

171. Gabbita SP, Srivastava MK, Eslami P, Johnson MF, Kobritz NK, Tweedie D, Boycott HE, Wilkinson JA, Boyle JP, Pearson HA, Peers C. Differential involvement of TNF alpha in hypoxic suppression of astrocyte glutamate transporters. Glia. 2008;56:998–1004.

161. Russo I, Caracciolo L, Tweedie D, Choi SH, Greig NH, Barlati S, Bosetti F. 3,6- Dithiothalidomide, a new TNF-alpha synthesis inhibitor, attenuates the effect of Abeta1-42 intracerebroventricular injection on hippocampal neurogenesis and memory deficit. J Neurochem. 2012;118:1181–92.

162. Song T, Ma X, Gu K, Yang Y, Yang L, Ma P, Wang W, Zhao J, Yan R, Guan J, et al. Thalidomide represses inflammatory response and reduces radiculopathic pain by inhibiting IRAK-1 and NF-kappaB/p38/JNK signaling. J Neuroimmunol. 2016;301:1–8.

163. Maekawa T, Ashihara E, Kimura S. The Bcr-Abl tyrosine kinase inhibitor AMN107 (nilotinib) normalizes striatal motor behaviors in a mouse model of Parkinson’s disease. Front Cell Neurosci. 2014;8:50.

165. Breccia M, Alimena G. Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia. Leuk Res. 2010;34:129–34.

164. Maekawa T, Ashihara E, Kimura S. The Bcr-Abl tyrosine kinase inhibitor AMN107 (nilotinib) normalizes striatal motor behaviors in a mouse model of Parkinson’s disease. Sci Rep. 2014;4:4874.
203. Lu TS, Avraham HK, Seng S, Tachado SD, Kozel H, Makiyannis A, Avraham S. Cannabinoids inhibit HIV-1 Gpl20-mediated insults in brain microvascular endothelial cells. J Immunol. 2008;181:6406–16.

204. Bari M, Rapino C, Mozetic P, Maccarrone M. The endocannabinoid system in gp120-mediated insults and HIV-associated dementia. Exp Neurol. 2010;224:74–84.

205. Kim HJ, Shin AH, Thayer SA. Activation of cannabinoid type 2 receptors inhibits HIV-1 envelope glycoprotein gp120-induced synapse loss. Mol Pharmocol. 2011;80:357–66.

206. Solbrig MV, Fan J, Hazelton P. Prospects for cannabinoid therapies in viral encephalitis. Brain Res. 2013;1537:237–82.

207. Hajos N, Ledent C, Freund TF. Novel cannabinoid-sensitive receptor in the rat CNS. Neuropharmacology. 2013;71:282–91.

208. Facchinetti F, Del Giudice E, Furegato S, Passarotto M, Leon A. Cannabinoids and lipopolysaccharide (LPS): effects on murine macrophages. Eur J Pharmocol. 2000;406:R5–7.

209. Hajs N, Ledent C, Freund TF. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neurosc. 2001;106:1–4.

210. Domenici MR, Azad SC, Marsicano G, Schierloh A, Wotjak CT, Dodt HU, Gerdeman G, Lovinger DM. CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J Neurophysiol. 2001;85:468–71.

211. Domenici MR, Azad SC, Marsicano G, Schierloh A, Wotjak CT, Dodt HU, Gerdeman G, Lovinger DM. CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J Neurophysiol. 2001;85:468–71.

212. Lu TS, Avraham HK, Seng S, Tachado SD, Kozel H, Makiyannis A, Avraham S. Cannabinoids inhibit HIV-1 Gpl20-mediated insults in brain microvascular endothelial cells. J Immunol. 2008;181:6406–16.

213. Lu TS, Avraham HK, Seng S, Tachado SD, Kozel H, Makiyannis A, Avraham S. Cannabinoids inhibit HIV-1 Gpl20-mediated insults in brain microvascular endothelial cells. J Immunol. 2008;181:6406–16.

214. Barzegar S, Komaki A, Shahidi S, Sarihi A, Mirazi N, Salehi I. Effects of cannabinoids on the rat hippocampus. Neuroscience. 2008;151:1095–102.

215. Rudomin MR, Azad SC, Marsicano G, Schierloh A, Wotjak CT, Dodt HU, Gerdeman G, Lovinger DM. CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J Neurophysiol. 2001;85:468–71.

216. Barzegar S, Komaki A, Shahidi S, Sarihi A, Mirazi N, Salehi I. Effects of cannabinoids on the rat hippocampus. Neuroscience. 2008;151:1095–102.

217. Hajos N, Ledent C, Freund TF. Novel cannabinoid-sensitive receptor in the rat CNS. Neuropharmacology. 2013;71:282–91.

218. Hajos N, Ledent C, Freund TF. Novel cannabinoid-sensitive receptor in the rat CNS. Neuropharmacology. 2013;71:282–91.

219. Domenici MR, Azad SC, Marsicano G, Schierloh A, Wotjak CT, Dodt HU, Gerdeman G, Lovinger DM. CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J Neurophysiol. 2001;85:468–71.

220. Takahashi KA, Castillo PE. The CB1 cannabinoid receptor mediates glutamatergic synaptic suppression in the hippocampus. Neuroscience. 2006;143:822–34.

221. Barzegar S, Komaki A, Shahidi S, Sarihi A, Mirazi N, Salehi I. Effects of cannabinoids on the rat hippocampus. Neuroscience. 2008;151:1095–102.

222. Coffey GL, Ehrlich J, Fisher MW, Hillegas AB, Kohberger DL, Machemer HE, Righelto WA, Roegner FR. 6-Diazo-5-oxo-L-norleucine, a new tumor-inhibitory substance. I. Biologic studies. Antisbiot Chemother (Northfield). 1956;6:487–90.

223. Conti F, Minelli A. Glutamate immunoreactivity in rat cerebral cortex is reversibly abolished by 6-diazo-5-oxo-L-norleucine (DON), an inhibitor of phosphate-activated glutaminase. J Histochern Cytochern. 1994;42:717–26.

224. Earhart RH, Koeller JM, Davis HL. Phase I trial of 6-diazo-5-oxo-L-norleucine (DON) administered by 5-day courses. Cancer Treat Rep. 1982;66:1215–7.
244. David CN, Frias ES, Szu JI, Vieira PA, Hubbard JA, Lovelace J, Michael M, Worth D, McGovern KE, Ethell IM, et al. GLT-1-dependent disruption of CNS glutamate homeostasis and neuronal function by the protozoan parasite Toxoplasma gondii. PLoS Pathog. 2016;12:e1005643.

245. Fumagalli E, Funicello M, Rauen T, Gabbi M, Meninini T. Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1. Eur J Pharmacol. 2008;578:171–6.

246. Carbone M, Duty S, Rattray M. Riluzole elevates GLT-1 activity and levels in striatal astrocytes. Neurochem Int. 2012;60:31–8.

247. Dall’Igna OP, Bobermin LD, Souza DO, Quincozes-Santos A. Riluzole increases glutamate uptake by cultured C6 astroglial cells. Int J Dev Neurosci. 2013;31:482–6.

248. Hunsberger HC, Weitzner DS, Rudy CC, Hickman JE, Libell EM, Speer RR, Gerhardt GA, Reed MN. Riluzole rescues glutamate alterations, cognitive deficits, and tau pathology associated with P301L tau expression. J Neurochem. 2015;135:381–94.

249. Pereira AC, Gray JD, Kogan JF, Davidson RL, Rubin TG, Okamoto M, Morrison JH, McEwen BS. Age and Alzheimer’s disease gene expression profiles reversed by the glutamate modulator riluzole. Mol Psychiatry. 2016